國創高新(002377.SZ)前三季淨利預降52.76%-61.26%
格隆匯10月14日丨國創高新(002377.SZ)發佈2020年前三季度業績預告,歸屬於上市公司股東的淨利潤9114.69萬元-1.11億元,同比減少52.76%-61.26%。其中,2020年第三季度歸屬於上市公司股東的淨利潤4500萬元-6500萬元,同比減少32.65%-53.37%。
本報告期業績下降的主要原因,一是受疫情影響,公司報告期收入較上年同期出現較大幅度下降;二是受市場需求結構變化影響,創利較高的新房代理業務收入較上年同期有較大幅度下降,創利較低的二手房經紀業務收入上升,同時新開店鋪成本費用有一定增加;三是為應對疫情影響,公司適當提高了經紀人分傭比例。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.